港股异动 | CRO概念股持续走高生物安全法案落地受阻头部企业投资情绪有望边际回暖

智通财经09-26

智通财经APP获悉，CRO概念股持续走高，截至发稿，泰格医药(03347)涨9.28%，报31.2港元；康龙化成(03759)涨4.85%，报11.24港元；昭衍新药(06127)涨4.8%，报7.64港元；药明康德(02359)涨3.53%，报44港元；药明生物(02269)涨2.69%，报13.76港元。消息面上，据美国国会官网，美《生物安全法》立法一事又有进展。在最新的修正案中，药明生物已经...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2470208672?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-09-26 15:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470208672","market":"hk","top_or_hot":-1,"title":"港股异动 | CRO概念股持续走高 生物安全法案落地受阻 头部企业投资情绪有望边际回暖","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，CRO概念股持续走高，截至发稿，泰格医药(03347)涨9.28%，报31.2港元；康龙化成(03759)涨4.85%，报11.24港元；昭衍新药(06127)涨4.8%，报7.64港元；药明康德(02359)涨3.53%，报44港元；药明生物(02269)涨2.69%，报13.76港元。消息面上，据美国国会官网，美《生物安全法》立法一事又有进展。在最新的修正案中，药明生物已经...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1187461.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | CRO概念股持续走高 生物安全法案落地受阻 头部企业投资情绪有望边际回暖</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | CRO概念股持续走高 生物安全法案落地受阻 头部企业投资情绪有望边际回暖\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-26 15:24 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1187461.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，CRO概念股持续走高，截至发稿，泰格医药(03347)涨9.28%，报31.2港元；康龙化成(03759)涨4.85%，报11.24港元；昭衍新药(06127)涨4.8%，报7.64港元；药明康德(02359)涨3.53%，报44港元；药明生物(02269)涨2.69%，报13.76港元。消息面上，据美国国会官网，美《生物安全法》立法一事又有进展。在最新的修正案中，药明生物已经...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1187461.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0417516902.SGD","symbol_name":"Allianz China Equity Cl AT Acc SGD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1187461.html","article_id":"2470208672","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470208672","pubTimestamp":1727335458,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"消息面上，据美国国会官网，美《生物安全法》立法一事又有进展。在最新的修正案中，药明生物已经被除名。交银国际指出，考虑到美联储正式启动降息、行业订单边际改善，预计头部CXO的投资情绪将边际回暖，但进一步估值修复或许需要更多业绩复苏的能见度。国信证券表示，随着海外投融资的逐季度恢复，美联储开启降息周期，部分CXO板块公司的收入及利润有望呈现逐季度环比改善趋势，海外业务占比大的公司有望改善更加明显。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","03759":"康龙化成","02269":"药明生物","LU0823426480.USD":"法巴中国股票经典Dis","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","BK1521":"挪威政府全球养老基金持仓","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","BK1610":"ETF&股票定投概念","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","03347":"泰格医药","LU1046422090.SGD":"Fidelity Pacific A-SGD","LU0140636845.USD":"施罗德大中华区股票A Acc","BK1141":"生命科学工具和服务","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","BK1576":"医药外包概念","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","06127":"昭衍新药","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","BK1589":"北水核心资产","LU1720050803.USD":"安联全方位中国股票基金","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","02359":"药明康德","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU0823426308.USD":"法巴中国股票基金","BK1583":"高瓴概念","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU2125910500.SGD":"Natixis WCM Global Emerging Markets Equity H-R/A SGD","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0181495838.USD":"施罗德新兴亚洲A Acc"},"translate_title":"Changes in Hong Kong stocks, CRO concept stocks continue to rise, the implementation of the biosafety bill is blocked, and the investment sentiment of leading companies is expected to pick up marginally","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02359":0.9,"03347":0.9,"03759":0.9,"06127":0.9,"02269":0.9},"content_text":"智通财经APP获悉，CRO概念股持续走高，截至发稿，泰格医药(03347)涨9.28%，报31.2港元；康龙化成(03759)涨4.85%，报11.24港元；昭衍新药(06127)涨4.8%，报7.64港元；药明康德(02359)涨3.53%，报44港元；药明生物(02269)涨2.69%，报13.76港元。消息面上，据美国国会官网，美《生物安全法》立法一事又有进展。在最新的修正案中，药明生物已经被除名。交银国际认为，美国生物安全法案未被纳入NDAA，意味着生物安全法案立法进一步被推迟，年内单独立法的可能性下降，同时S.3558号法案最新版未纳入药明生物，根据美国立法流程，该行认为其他被提及的公司也有最终被除名的可能。交银国际指出，考虑到美联储正式启动降息、行业订单边际改善，预计头部CXO的投资情绪将边际回暖，但进一步估值修复或许需要更多业绩复苏的能见度。国信证券表示，随着海外投融资的逐季度恢复，美联储开启降息周期，部分CXO板块公司的收入及利润有望呈现逐季度环比改善趋势，海外业务占比大的公司有望改善更加明显。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470208672"}

港股异动 | CRO概念股持续走高 生物安全法案落地受阻 头部企业投资情绪有望边际回暖

精彩评论

港股异动 | CRO概念股持续走高生物安全法案落地受阻头部企业投资情绪有望边际回暖